Barrett Esophagus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Barrett esophagus markets are expected to exhibit a CAGR of 4.9% during 2024-2034.
The Barrett esophagus market has been comprehensively analyzed in IMARC's new report titled "Barrett Esophagus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Barrett esophagus is a precancerous condition characterized by the substitution of the typical stratified squamous epithelium lining of the esophagus with a columnar epithelium. This cellular alteration occurs in response to chronic acid reflux, where stomach acid frequently washes back into the esophagus, causing damage and inflammation. The symptoms of the illness are generally similar to those experienced in gastroesophageal reflux disease (GERD), which includes heartburn, regurgitation, and difficulty swallowing. However, some individuals suffering from the ailment may not exhibit any overt indications. The diagnosis involves an endoscopy procedure where a thin, flexible tube with a camera is inserted into the mouth to visualize the esophagus. Biopsy samples are also collected to confirm the presence of columnar cells and rule out dysplasia or cancer. If Barrett esophagus is confirmed, regular surveillance endoscopies are often recommended to monitor for any cellular changes that might indicate a progression toward cancer.
The increasing incidences of GERD, in which stomach acid travels back into the esophagus, causing discomfort and inflammation over time, are primarily driving the Barrett esophagus market. In addition to this, the inflating utilization of proton pump inhibitors, H2 blockers, and antacids to manage acid reflux and mitigate the risk of disease complications is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, including dietary adjustments and weight management, as they aid in reducing acid reflux and potentially slowing the progression of the ailment, is further bolstering the market growth. Apart from this, the rising usage of radiofrequency ablation and cryotherapy procedures, targeting the abnormal esophageal tissues and promoting their removal or destruction, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine approaches, which tailor treatment strategies based on a patient's genetic predispositions, is also augmenting the market growth. These advancements could involve the identification of genetic markers associated with the disease's progression and treatment response, leading to more effective interventions. Furthermore, the escalating application of minimally invasive surgical procedures, like fundoplication, that are designed to enhance the functionality of the lower esophageal sphincter is expected to drive the Barrett esophagus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Barrett esophagus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Barrett esophagus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Barrett esophagus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Barrett esophagus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Barrett esophagus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Barrett esophagus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Barrett esophagus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Barrett esophagus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Barrett esophagus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Barrett esophagus across the seven major markets?
What is the number of prevalent cases (2018-2034) of Barrett esophagus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Barrett esophagus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Barrett esophagus across the seven major markets?
What is the size of the Barrett esophagus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Barrett esophagus?
What will be the growth rate of patients across the seven major markets?
Barrett Esophagus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Barrett esophagus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Barrett esophagus market?
What are the key regulatory events related to the Barrett esophagus market?
What is the structure of clinical trial landscape by status related to the Barrett esophagus market?
What is the structure of clinical trial landscape by phase related to the Barrett esophagus market?
What is the structure of clinical trial landscape by route of administration related to the Barrett esophagus market?
The Barrett esophagus market has been comprehensively analyzed in IMARC's new report titled "Barrett Esophagus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Barrett esophagus is a precancerous condition characterized by the substitution of the typical stratified squamous epithelium lining of the esophagus with a columnar epithelium. This cellular alteration occurs in response to chronic acid reflux, where stomach acid frequently washes back into the esophagus, causing damage and inflammation. The symptoms of the illness are generally similar to those experienced in gastroesophageal reflux disease (GERD), which includes heartburn, regurgitation, and difficulty swallowing. However, some individuals suffering from the ailment may not exhibit any overt indications. The diagnosis involves an endoscopy procedure where a thin, flexible tube with a camera is inserted into the mouth to visualize the esophagus. Biopsy samples are also collected to confirm the presence of columnar cells and rule out dysplasia or cancer. If Barrett esophagus is confirmed, regular surveillance endoscopies are often recommended to monitor for any cellular changes that might indicate a progression toward cancer.
The increasing incidences of GERD, in which stomach acid travels back into the esophagus, causing discomfort and inflammation over time, are primarily driving the Barrett esophagus market. In addition to this, the inflating utilization of proton pump inhibitors, H2 blockers, and antacids to manage acid reflux and mitigate the risk of disease complications is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle modifications, including dietary adjustments and weight management, as they aid in reducing acid reflux and potentially slowing the progression of the ailment, is further bolstering the market growth. Apart from this, the rising usage of radiofrequency ablation and cryotherapy procedures, targeting the abnormal esophageal tissues and promoting their removal or destruction, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of personalized medicine approaches, which tailor treatment strategies based on a patient's genetic predispositions, is also augmenting the market growth. These advancements could involve the identification of genetic markers associated with the disease's progression and treatment response, leading to more effective interventions. Furthermore, the escalating application of minimally invasive surgical procedures, like fundoplication, that are designed to enhance the functionality of the lower esophageal sphincter is expected to drive the Barrett esophagus market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the Barrett esophagus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Barrett esophagus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Barrett esophagus market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Barrett esophagus market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Barrett esophagus market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Barrett esophagus marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Barrett esophagus market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Barrett esophagus market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Barrett esophagus market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Barrett esophagus across the seven major markets?
What is the number of prevalent cases (2018-2034) of Barrett esophagus by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Barrett esophagus by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Barrett esophagus across the seven major markets?
What is the size of the Barrett esophagus patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Barrett esophagus?
What will be the growth rate of patients across the seven major markets?
Barrett Esophagus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Barrett esophagus drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Barrett esophagus market?
What are the key regulatory events related to the Barrett esophagus market?
What is the structure of clinical trial landscape by status related to the Barrett esophagus market?
What is the structure of clinical trial landscape by phase related to the Barrett esophagus market?
What is the structure of clinical trial landscape by route of administration related to the Barrett esophagus market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BARRETT ESOPHAGUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BARRETT ESOPHAGUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BARRETT ESOPHAGUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BARRETT ESOPHAGUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BARRETT ESOPHAGUS - UNMET NEEDS
10 BARRETT ESOPHAGUS - KEY ENDPOINTS OF TREATMENT
11 BARRETT ESOPHAGUS - MARKETED PRODUCTS
11.1 List of Barrett Esophagus Marketed Drugs Across the Top 7 Markets
11.1.1 Photofrin (Porfimer Sodium) - Pinnacle Biologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BARRETT ESOPHAGUS - PIPELINE DRUGS
12.1 List of Barrett Esophagus Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. BARRETT ESOPHAGUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BARRETT ESOPHAGUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BARRETT ESOPHAGUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Barrett Esophagus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Barrett Esophagus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Barrett Esophagus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Barrett Esophagus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Barrett Esophagus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Barrett Esophagus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Barrett Esophagus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Barrett Esophagus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Barrett Esophagus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Barrett Esophagus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Barrett Esophagus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Barrett Esophagus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Barrett Esophagus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Barrett Esophagus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Barrett Esophagus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Barrett Esophagus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Barrett Esophagus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Barrett Esophagus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Barrett Esophagus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Barrett Esophagus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Barrett Esophagus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Barrett Esophagus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Barrett Esophagus - Access and Reimbursement Overview
16 BARRETT ESOPHAGUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BARRETT ESOPHAGUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BARRETT ESOPHAGUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 BARRETT ESOPHAGUS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 BARRETT ESOPHAGUS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 BARRETT ESOPHAGUS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 BARRETT ESOPHAGUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 BARRETT ESOPHAGUS - UNMET NEEDS
10 BARRETT ESOPHAGUS - KEY ENDPOINTS OF TREATMENT
11 BARRETT ESOPHAGUS - MARKETED PRODUCTS
11.1 List of Barrett Esophagus Marketed Drugs Across the Top 7 Markets
11.1.1 Photofrin (Porfimer Sodium) - Pinnacle Biologics
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 BARRETT ESOPHAGUS - PIPELINE DRUGS
12.1 List of Barrett Esophagus Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. BARRETT ESOPHAGUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. BARRETT ESOPHAGUS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 BARRETT ESOPHAGUS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Barrett Esophagus - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Barrett Esophagus - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Barrett Esophagus - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Barrett Esophagus - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Barrett Esophagus - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Barrett Esophagus - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Barrett Esophagus - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Barrett Esophagus - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Barrett Esophagus - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Barrett Esophagus - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Barrett Esophagus - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Barrett Esophagus - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Barrett Esophagus - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Barrett Esophagus - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Barrett Esophagus - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Barrett Esophagus - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Barrett Esophagus - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Barrett Esophagus - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Barrett Esophagus - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Barrett Esophagus - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Barrett Esophagus - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Barrett Esophagus - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Barrett Esophagus - Access and Reimbursement Overview
16 BARRETT ESOPHAGUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 BARRETT ESOPHAGUS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 BARRETT ESOPHAGUS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
